09.03.2011Frost & Sullivan Award Commends AugurixYou are hereNewsFrost & Sullivan Award Commends Augurix
The 2010 Frost & Sullivan European Product Differentiation Excellence Award in Point of Care Testing is presented to Augurix. The company is honored for developing the Simtomax test - the only known point of care test for screening Celiac disease that reaches lab-accurate results.
The Product Differentiation Excellence Award is awarded to the company that has excelled in the following criteria: unique features/functionality, quality/complexity, matched to target markets needs and brand perception of the uniqueness of the product.
LS2 Annual Meeting 201812.02.2018The biggest Life Sciences conference in Switzerland takes place at the University of Lausanne February 12-13, 2018
Bilan - Les Métiers de DemainLe magazine référence nous informe des nouvelles formations et de leur impact sur l'avenir des métiers de la santé...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.